• Exozymes secured a $2.03 million NIH NIGMS Phase IIB SBIR grant to advance rare cannabinoids and engineered cannabinoid analogs for drug discovery.
• Work is slated to start July 1, 2026, targeting scale-up of enzyme systems and preclinical receptor-binding assays for its cannabinoid library.
• Occidental College, via Vikram Shende’s lab, will receive a sub-award under the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-030205), on June 26, 2026, and is solely responsible for the information contained therein.